HALBERD CORPORATION holds the exclusive rights to the COVID-19 extracorporeal treatment technology
(based on granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and 6 provional COVID-19 patents)
HALB Security Details - https://www.otcmarkets.com/stock/HALB/security
Authorized Shares - 800,000,000 - a/o 11/06/2020
Shares Outstanding - 317,721,539 - a/o 11/06/2020
Float- 260,484,414 - a/o 11/06/2020
Halberd Corp. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.
It is debt-free and holds the exclusive rights to six COVID-19 extracorporeal treatment technology provisional patent applications:
"Method for Treating and Curing Covid-19 Infection;"
"Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients"
"Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus"
"Nasal spray to Prevent the Transmission of COVID-19 between Humans"
"Nasal Spray to Prevent the Transmission of Covid-19"
"Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus"
HALB also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287
Halberd Corp has a joint venture on Covid-19 treatment that starts with Dr. Mitchell Felder’s patented extracorporeal therapy (US Patent 9,216,386 and US Patent 8,758,287) for the safe removal of targeted antigens from the blood and targeted organs. Dr. Felder explained, “The extracorporeal treatment is based on the process of removing the underlying basis of the disease. In the case of Covid-19, it entails removal of specific compounds which allow the virus to replicate. We believe this technology is superior to known treatments in that it may potentially eliminate mutations of the virus.” Dr. Felder continued, “With our partners, including a leading university partner, we are now positioned to develop potential cures and mitigation for Covid-19 as well as to alleviate the global drug epidemic for our country and the world. The joint venture includes financial commitments for funding, which if obtained, along with the continued research with our university partner is likely to develop the technology disclosed in our provisional patent application entitled ‘Method for Treating and Curing COVID-19 Infection’. We seek to further develop and establish proof of concept with regard to these promising tools in this worldwide battle. This positions us to facilitate defenses against the growing COVID-19 menace as well as against other viral attacks.”
See YouTube video, https://youtu.be/BGdZqHH6oew, concerning Dr. Felder’s discussion of the scientific basis underlying Premier’s extracorporeal treatment process for fighting cancer and other diseases.
In plain English: HALB with its partners is developing an extra-corporeal (out of the body) treatment against COVID-19
and other virusses and diseases. With the use of antibodies the coronavirus disease antigens is targeted. With a nano laser
technology antigens and cytokines are eradicated. All based on 2 granted patents and 6 provisional patents.
JACKSON CENTER, PA / ACCESSWIRE / August 4, 2020 / Halberd Corp. (OTC PINK:HALB) announced today that they have secured non-dilutive, grant-based funding for their patent pending Covid-19 treatment(s). Newly formed Nonprofit Organization, Epidemiologic Solutions Corporation, a Louisiana, Internal Revenue Code Section 501(c)(3) application pending, has committed to provide funding of approximately $2,000,000, as required by Halberd Corporation and its research partners
Halberd Selects Arizona State University (ASU) to Develop Its Patented COVID-19 Treatment(s)
JACKSON CENTER, PA / ACCESSWIRE / August 31, 2020 / Halberd Corporation (OTC PINK:HALB) today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd's Covid-19 treatments. The work will focus on developing antibodies in support of Halberd's two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of the virus' antigens from a patient's blood. It will also focus on neutralizing the effects of antigens and development of a potential therapeutic medication. William A. Hartman, Chairman, President and CEO of Halberd Corporation stated, "ASU has demonstrated its expertise in biomedical research, including in the coronavirus arena through its recent development of the first Covid-19 saliva-based diagnostic test." Here's the link to the full $1.4 million Research & Development agreement between Halberd Corp. and Arizona State University / The Biodesign Institute:
On May 12th 2020 MARV Enterprises LLC, Premier Biomedical Inc and Halberd Corp (THI) signed an Intellectual Property Agreement (exhibit 10.2), transfering the exclusive rights to the 2 above mentioned granted US Patents and the mentioned 4 provisional Patents exclusively to Halberd Corp:
Jackson Center, PA, October 13, 2020 – Halberd Corporation (OTC PINK: “HALB“) reported that Arizona State University researchers, utilizing the intellectual property of Halberd Corporation, have successfully generated an anti-Spike protein monoclonal antibody against Covid-19. The Spike Protein is a main component of the Covid-19 virus, and is a crucial component in its ability to replicate. In addition, the researchers have sent for synthesis, genes for the creation of new, unique monoclonal antibodies against the SARS-CoV-2 Spike Protein. The performance has exceeded expectations, and Halberd and ASU intend to file for joint patent protection.
JACKSON CENTER, PA / ACCESSWIRE / October 19, 2020 / Halberd Corporation (OTC PINK:HALB) today announced the creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. The discovery is the result of Halberd's research in conjunction with Arizona State University's Dr. Qiang "Shawn" Chen, utilizing Halberd's intellectual property created by Mitchel S. Felder, MD. Halberd and ASU have begun the process of filing the first of multiple planned joint patent applications for this new class of antibody.
This engineered monoclonal antibody against the Covid-19 virus spike protein may allow for an extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, blood and urine. It may also potentially allow for the rapid identification of the Covid-19 virus present on surfaces, such as food, cell phones, door handles, etc., through testing only a small sample.
Jackson Center, PA, November 9, 2020 – Halberd Corp. (OTC PINK: “HALB“) reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, “Nasal Spray to Prevent the Transmission of Covid-19,” discloses a combination of proprietary Covid-19 Spike Protein antibodies, ACE2 antibody, and Neuropilin-1 antibodies. This application builds on, and is an improvement to an earlier provisional patent application, “Nasal Spray to Prevent the Transmission of Covid-19 Between Humans.”
Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: “HALB“) today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University. The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 antigens. Halberd is working to develop this fluorescent antibody into a rapid test mechanism for detecting Covid-19 antigens from saliva or blood, which could provide results in minutes instead of other fluorescent methods already on the market that take a couple of hours or more to display test results. We are working on a handheld device to easily detect the fluorescent light emitted when the antibody contacts Covid-19 antigens.
JACKSON CENTER, PA / ACCESSWIRE / November 19, 2020 / Halberd Corp. (OTC PINK:HALB) reported the filing of a provisional patent application on a variation of Halberd's patented extracorporeal method to treat/eradicate Covid-19 from a patient's blood. By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects than with more conventional treatment regimens. Halberd's provisional patent application, "Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus," discloses a unique application of extracorporeal exposure of virus-infected blood to a specifically created antibody which has been demonstrated to bind with the virus, but without deleterious side effects. This conjugate antibody/antigen pair is designed to react to an externally applied specific radio frequency which destroys the virus-antibody pair in real-time.
Trademarkia Trademark (11/07/2020) FELDER-HALBERD-ASU MONOCLONAL ANTIBODY Trademark Information
Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing;
Dietary and nutritional supplements containing monoclonal antibody for use in immune system support;
Pharmaceutical preparations for the treatment and prevention of Covid-19;
Pharmaceutical preparations for the treatment of immune system related diseases and disorders
The claim the VA is working with this scam is a totally false and blatent lie! The VA Does not work with shell companies that have no assets.
Datatecnics Corp is a privately held company so what would they have anything to do with a scam like Halberd?
Halberd holds no patents as they are held by Marv Enterprises
It is all a scam. Richard Goulding needs 1.8 Million to pay the fine from the SEC. This has always been a scam shell to bilk money out of investors.
This is the new company headquarters at 1174 East Kingston Square, Lake Charles, Louisiana 70611
Nothing like having a company headquartered out of a DOUBLE WIDE on a foundation with a trashy yard.
This scam is committing fraud as they are advertising Halberd as having 800 Million shares when Halberd Corp no longer exists. All the stock and ticker was transferred to Halberd Transition Corporation under Alaric Corporation on 05-14-2020 with 2 Billion common shares. Read the CO SoS filing carefully.
What does a business selling scam, a drone scam, a beer tap scam, a pot scam and a virus scam have in common? None have so far created a successful business but they have ripped off many investors of their money and Halberd is the culprit.
Be very cautious if trading this scam. The ticker was transfered to Alaric Corp and renamed Halbered Transition Corp back on 03-27-2020. What you think you are trading has no trading symbol. This is a scam. Read the filings at CO SOS.